ReviewCancer management and research2025
Application of Liquid Biopsy Technology in Lung Cancer: A Bibliometric Study and Visualization Analysis.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is a major global health threat, and traditional treatments are hindered by tumor heterogeneity and drug resistance. Liquid biopsy technology offers new opportunities for precise diagnosis and treatment of lung cancer; however, its clinical application still presents challenges. Therefore, we aimed to elucidate the research progress and future trends of liquid biopsy technology through a bibliometric analysis. Methods: Literature on liquid biopsy technology in lung cancer research spanning from 1990 to 2024 was retrieved from the Web of Science Core Collection. Various bibliometric tools were employed, including VOSviewer (1.6.20), Cite Space (6.2.R3), RStudio (utilizing the R package bibliometrix), and Scimago Graphica, to explore the current situation and research hotspots in this area. The research covered multiple aspects, including publication counts, contributions from different countries and institutions, journals involved, authorship, co-references, and keywords. By generating corresponding visualization maps, an attempt was made to forecast future development trends within this research field. Results: We identified 363 articles published in 198 journals, authored by 2518 authors from 266 institutions across 54 countries/regions. The journal, country, institution, and author with the highest number of publications were Cancer, China, Harvard University, and ROLFO C. Over the past 34 years, research on the application of liquid biopsy technology in lung cancer have primarily focused on cancer diagnosis, biomarkers, and treatment monitoring. Conclusion: Liquid biopsy technology is rapidly evolving in the field of lung cancer. Detecting biomarkers such as circulating tumor DNA, circulating tumor cells, and extracellular vesicles, facilitates early detection and monitoring of treatment response, reveals drug resistance mechanisms, and promotes personalized treatment. With the advancement of technology and international cooperation, liquid biopsy is expected to provide more accurate diagnosis and treatment for patients with lung cancer in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.